Physicians Healthsource Inc v. Cephalon Inc

954 F.3d 615
CourtCourt of Appeals for the Third Circuit
DecidedMarch 30, 2020
Docket18-3609
StatusPublished
Cited by118 cases

This text of 954 F.3d 615 (Physicians Healthsource Inc v. Cephalon Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Physicians Healthsource Inc v. Cephalon Inc, 954 F.3d 615 (3d Cir. 2020).

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________

No. 18-3609 _____________

PHYSICIANS HEALTHSOURCE, INC., an Ohio Corporation, individually and as the representative of a class of similarly-situated persons, Appellant

v.

CEPHALON, INC.; CEPHALON CLINICAL PARTNERS, L.P.; CEPHALON DEVELOPMENT CORPORATION; SCIMEDICA GROUP, LLC; SCIMEDICA GROUP MARKETING RESEARCH AND CONSULTING, LLC; JOHN DOES 1-10

and

SCIMEDICA GROUP, LLC; SCIMEDICA GROUP MARKETING RESEARCH AND CONSULTING, LLC, Third-Party Plaintiffs v.

BLITZ RESEARCH, INC., Third-Party Defendant

______________ On Appeal from the United States District Court for the Eastern District of Pennsylvania (D.C. Civil No. 2:12-cv-03753) District Judge: Honorable John R. Padova ______________

Submitted Under Third Circuit L.A.R. 34.1(a) October 21, 2019 ______________

Before: GREENAWAY, JR., PORTER, and COWEN, Circuit Judges.

(Opinion Filed: March 30, 2020)

Jeffrey A. Berman, Esq. Glenn L. Hara, Esq. Anderson & Wanca 3701 Algonquin Road Suite 500 Rolling Meadows, IL 60008 Counsel for Appellant

Nicholas H. Pennington, Esq. Joseph E. Wolfson, Esq. Stevens & Lee 620 Freedom Business Center Suite 200 King of Prussia, PA 19406 Counsel for Appellees Cephalon, Inc.; Cephalon Clinical Partners, LP; Cephalon Development Corp.

2 Sheryl S. Levy, Esq. Cooper Schall and Levy 1204 Township Line Road Drexel Hill, PA 19026 Counsel for Appellees SciMedica Group, LLC; SciMedica Group Marketing Research and Consulting LLC

______________

OPINION OF THE COURT ______________

GREENAWAY, JR., Circuit Judge.

In this digital age with myriad forms of communication, faxes no longer dominate, as they once did. Yet, faxes are the focus of our attention today. Although complicated by a phalanx of parties, the essence of this dispute is whether a pharmaceutical company violated a federal statute by impermissibly sending two faxes to a doctor.

The plaintiff-appellant in this case is Physicians Healthsource, Inc. (“PHI”), the prior employer of the doctor, who was the recipient of the faxes. The appellees in this case are Cephalon, Inc., Cephalon Clinical Partners, L.P., and Cephalon Development Corporation (collectively “Cephalon”), and SciMedica Group, LLC and SciMedica Group Marketing Research and Consulting, LLC (“SciMedica” collectively with

3 Cephalon “Defendants”).1 Cephalon drug representatives met with the PHI doctor on multiple occasions to discuss various pharmaceutical drugs. The two faxes in dispute were sent to the PHI doctor on behalf of Cephalon.

PHI believes these faxes were unsolicited and thus sent in violation of the Telephone Consumer Protection Act of 1991 (“TCPA”), Pub. L. No. 102-243, 105 Stat. 2394, as amended by the Junk Fax Prevention Act of 2005 (“JFPA”), Pub. L. No. 109-21, 119 Stat. 359 (codified as amended at 47 U.S.C. § 227, collectively referred to herein as the “TCPA”). Additionally, PHI argues that if the faxes are found to be solicited, they nevertheless violated the TCPA by failing to include opt-out language.

The District Court granted summary judgment in favor of Defendants, finding that there was no genuine dispute of material fact that the faxes were solicited and that the TCPA does not require solicited faxes to contain opt-out notices. For the reasons detailed below, we will affirm.

I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY

In 2009, two faxes were sent to Dr. Jose Martinez on behalf of Cephalon.2 At the time, Dr. Martinez worked for PHI,

1 Blitz Research, Inc. (“Blitz”) is a third-party defendant, and SciMedica Group, LLC and SciMedica Group Marketing Research and Consulting, LLC are third-party plaintiffs. 2 At summary judgment, Cephalon argued that the faxes were sent by SciMedica, while SciMedica contended the two faxes were transmitted by Blitz, and so SciMedica filed a crossclaim

4 practiced in the area of pain management, and met with Cephalon drug representatives on various occasions to discuss different Cephalon drugs. During certain visits, Cephalon representatives asked Dr. Martinez if they could follow up with him and “send [him] things,” after which faxes were sometimes then sent, faxes that Dr. Martinez never told Cephalon or its representatives to stop sending. JA195. Here though, only two faxes are in dispute.

The first fax at issue, addressed to Dr. Martinez, was an invitation to a dinner meeting program on a drug called AMRIX®. The second fax was an invitation to a promotional product lunch on FENTORA®. Both drugs are pain medications, and both are drugs that Dr. Martinez had discussed with Cephalon representatives previously. Indeed, at his request, Dr. Martinez had received samples of AMRIX® on multiple occasions. Neither fax included opt-out language (i.e., language informing the recipient that he or she could decline future faxes).

Importantly, it is undisputed that PHI provided its fax number to Defendants via business cards. PHI concedes that “at best, Defendants marshalled enough evidence at summary judgment to show . . . [PHI’s] voluntary communication” of its fax number to Defendants. Appellant’s Br. 24 (internal quotation marks omitted) (emphasis added). And during his deposition, Dr. Martinez noted that the business cards, with the fax number

against Blitz. It is undisputed that Cephalon had another party send the faxes on its behalf, and for the purpose of resolving this appeal whether SciMedica sent the faxes or Blitz sent the faxes is immaterial.

5 in question, were made available to drug representatives, so that they could get in touch with him.

Nevertheless, believing these faxes were sent in violation of the TCPA, PHI subsequently filed a putative class action complaint asserting damages, as “[u]nsolicited faxes damage their recipients . . . [who] lose[] the use of [their] fax machine, paper, and ink toner.” Docket 1. PHI thus asserted that it was entitled to either its actual monetary losses or statutory damages, whichever was greater, because Defendants sent unsolicited faxes that failed to contain opt-out notices.

Defendants filed summary judgment motions claiming the two faxes were not subject to the TCPA’s requirements because they were sent with prior express permission, meaning they were solicited and thus not prohibited by the TCPA, and also arguing that solicited faxes did not need to contain opt-out notices.3 The District Court granted both summary judgment motions. See Physicians Healthsource, Inc. v. Cephalon, Inc., 340 F. Supp. 3d 445, 453–54 (E.D. Pa. 2018). PHI timely appealed.

II. JURISDICTION AND STANDARD OF REVIEW

The District Court had jurisdiction under 28 U.S.C. § 1331, and we have jurisdiction under 28 U.S.C. § 1291. Our review of a district court’s grant of summary judgment is plenary, and we apply the same standard as the district court to determine whether summary judgment was appropriate. Jester v. Hutt, 937 F.3d 233, 238 (3d Cir. 2019). Summary judgment is appropriate only when “there is no genuine dispute as to any

3 SciMedica adopted the arguments set forth by Cephalon.

6 material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
954 F.3d 615, Counsel Stack Legal Research, https://law.counselstack.com/opinion/physicians-healthsource-inc-v-cephalon-inc-ca3-2020.